CAMILLE MULLER: Open Payments
NPI 1790230613 · FORT PIERCE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,140 in 134 payments from 17 companies in 2025. Trend: 2023 $2,462 · 2024 $2,419 · 2025 $3,140
Food & beverage: $3,140
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $652 |
| Neurocrine BioSciences, Inc. | 26 | $522 |
| Teva Pharmaceuticals USA, Inc. | 13 | $423 |
| Alkermes, Inc. | 16 | $335 |
| Otsuka America Pharmaceutical, Inc. | 12 | $253 |
| E.R. Squibb & Sons, L.L.C. | 10 | $235 |
| Janssen Pharmaceuticals, Inc | 7 | $182 |
| Vanda Pharmaceuticals Inc. | 8 | $141 |
| ABBVIE INC. | 7 | $136 |
| TMS NeuroHealth Centers Inc. | 2 | $44 |
Products named: CAPLYTA, INGREZZA, ARISTADA, AUSTEDO XR, COBENFY, INVEGA SUSTENNA, FANAPT, VRAYLAR.
Industry payments across FL — which companies pay providers there.
